- 654-53-5Benzene,1,2,3,4-tetrafluoro-5-(trifluoromethyl)-
- 65454-19-5Trichotoxin
- 65454-25-3Ussamycin (9CI)
- 65454-59-3Sulfomycin
- 6545-54-62-bromo-1,1'-iminodianthraquinone
- 65455-52-9Percoll
- 6545-58-0SERPENTINE NITRATE
- 6545-99-9Phebalosin
- 65460-52-8Titanate(2-),bis[bis(2-ethylhexyl) phosphito-kO'']tetrakis(2-propanolato)-, hydrogen (1:2)
- 654-62-61,3-Benzenedisulfonamide,4-amino-6-(trifluoromethyl)-
Hot Products
- 78-83-12-Methyl-1-propanol
- 86-74-8Carbazole
- 320-51-4Benzenamine,4-chloro-3-(trifluoromethyl)-
- 107-96-0Propanoicacid, 3-mercapto-
- 7048-04-6L-Cysteine hydrochloride monohydrate
- 192725-17-0Lopinavir
- 75-98-9Pivalic acid
- 5173-46-6Estra-4,9-diene-3,17-dione
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Salicylamide |
EINECS | 200-609-3 |
| CAS No. | 65-45-2 | Density | 1.286 g/cm3 |
| PSA | 63.32000 | LogP | 1.19140 |
| Solubility | <0.1 g/100 mL at 20 °C in water | Melting Point |
140-144 °C(lit.) |
| Formula | C7H7NO2 | Boiling Point | 318.3 °C at 760 mmHg |
| Molecular Weight | 137.138 | Flash Point | 146.3 °C |
| Transport Information | UN 3249 | Appearance | white or light pink crystals or powder |
| Safety | 26-36 | Risk Codes | 22-36/37/38-20/21/22 |
| Molecular Structure |
|
Hazard Symbols |
 Xn
|
| Synonyms |
Salamide;Saliamid;Saliamin;Salicim;Salicylic acid amide;Salipur;Salizell;Salrin;Salymid;Samid;Serramida;Urtosal;o-Hydroxybenzamide;Benzamide,2-hydroxy-;Salicylamide(8CI);2-Carbamoylphenol;2-Carboxamidophenol;2-Hydroxybenzamide;Afko-Sal;Algamon;Algiamida;Allevin;Amid-Sal;Amidosal;Anamid;Benesal;Cetamide;Cidal;Dropsprin;Liquiprin;Morsarinas;Novecyl;Oramid;Panithal;Raspberin;Salamid; |
Article Data | 146 |
Salicylamide Synthetic route
- 56429-60-8
2-ethyl-4-oxo-1,3-benzoxazinium perchlorate
- 95-54-5
1,2-diamino-benzene
A
- 138118-62-4
2-Ethyl-1H-benzoimidazole; compound with perchloric acid
B
- 65-45-2
salicylamide
| Conditions | Yield |
|---|---|
| at 100℃; for 0.0833333h; | A 100% B n/a |
- 17999-25-6
methyl thiosalicylate
- 65-45-2
salicylamide
| Conditions | Yield |
|---|---|
| With ammonia In dichloromethane at 20℃; for 6h; | 100% |
- 65-45-2
salicylamide
| Conditions | Yield |
|---|---|
| With hydrogenchloride In diethyl ether at 20℃; for 0.0166667h; | 98% |
- 54789-70-7
2-methyl-4-oxo-4H-benzo[e][1,3]oxazinium perchlorate
- 95-54-5
1,2-diamino-benzene
A
- 1792-35-4
2-(methyl)benzimidazolium perchlorate
B
- 65-45-2
salicylamide
| Conditions | Yield |
|---|---|
| at 100℃; for 0.0833333h; Product distribution; Mechanism; other 1,3-heterocyclic cations, other 1,4-binucleophiles; | A 97% B 96% |
| at 100℃; for 0.0833333h; | A 97% B 96% |
| Conditions | Yield |
|---|---|
| With ammonia In methanol at 50℃; for 16h; Sealed tube; | 94% |
| With sodium metabisulfite; ammonium hydroxide at 40℃; for 8h; Reagent/catalyst; Temperature; | 93.5% |
| With ammonia In aq. buffer at 45 - 50℃; under 760.051 Torr; for 1h; Reagent/catalyst; Temperature; | 86.2% |
| Conditions | Yield |
|---|---|
| With water at 150℃; under 5171.62 - 6205.94 Torr; for 0.5h; Inert atmosphere; Microwave irradiation; | 93% |
| With Acetaldehyde oxime; [(eta.(5)-pentamethylcyclopentadienyl)Rh(H2O)3](OTf)2 In water at 50℃; for 6h; Schlenk technique; | 86% |
| With N-ethyl-N-hydroxy-ethanamine; water; copper diacetate In ethanol at 35℃; for 3h; | 85% |
- 65-45-2
salicylamide
| Conditions | Yield |
|---|---|
| With toluene-4-sulfonic acid In toluene for 2h; Heating; | 92% |
| Conditions | Yield |
|---|---|
| With hydroxylamine hydrochloride In acetonitrile for 0.0652778h; Microwave irradiation; | 92% |
| With hydroxylamine hydrochloride; methanesulfonyl chloride In neat (no solvent) at 70℃; for 3.5h; | 91% |
| With triacetonitrile 4′-(4-chlorophenyl)-2,2′:6′,2″-terpyridine ruthenium(II) nitrate; hydroxylamine hydrochloride; sodium acetate In water at 100℃; for 12h; Inert atmosphere; | 75% |
- 74405-16-6
2,2-dimethyl-4-(2-oxo-1H-pyrid-1-yl)oxy-2H-1,3-benzoxazine
A
- 13161-30-3
2-hydroxy-pyridine N-oxide
B
- 65-45-2
salicylamide
| Conditions | Yield |
|---|---|
| With hydrogenchloride for 3h; Product distribution; Ambient temperature; | A 90% B n/a |
| Conditions | Yield |
|---|---|
| With aluminum oxide; hydroxylamine hydrochloride; methanesulfonyl chloride; water at 100℃; for 1h; | 90% |
| With hydroxylamine hydrochloride; zinc(II) oxide at 140℃; for 2h; Beckmann rearrangement; | 80% |
| With hydroxylamine hydrochloride; titanium(IV) oxide at 140℃; for 3h; Beckmann rearrangement; | 80% |
| Stage #1: 2-methyl-benzyl alcohol With aluminum oxide; methanesulfonic acid at 100℃; Beckmann rearrangement; Stage #2: With hydroxylamine hydrochloride at 140℃; for 2.5h; | 80 % Spectr. |
Salicylamide Chemical Properties
.jpg)
IUPAC Name: 2-Hydroxybenzamide
Molecular Formula: C7H7NO2
Molecular Weight: 137.14 g/mol
SMILES: O=C(c1ccccc1O)N Copy
InChI: InChI=1/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)
EINECS: 200-609-3
Classification Code: Analgesic; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Drug / Therapeutic Agent; Peripheral Nervous System Agents; Reproductive Effect; Sensory System Agents; Skin / Eye Irritant
Index of Refraction: 1.612
Molar Refractivity: 37.06 cm3
Molar Volume: 106.5 cm3
Surface Tension: 60.1 dyne/cm
Density: 1.286 g/cm3
Flash Point: 146.3 °C
Enthalpy of Vaporization: 58.21 kJ/mol
Boiling Point: 318.3 °C at 760 mmHg
Melting Point: 140-144 °C(lit.)
solubility: methanol: 0.1 g/mL, clear
Water Solubility: <0.1 g/100 mL at 20 °C
Stability: Stable. Light sensitive. Incompatible with strong bases, strong oxidizing agents.
Vapour Pressure of Salicylamide (CAS NO.65-45-2): 0.000195 mmHg at 25 °C
Salicylamide Uses
Salicylamide (CAS NO.65-45-2) is used in combination with both aspirin and caffeine in the over-the-counter pain remedy known as BC Powder.
Salicylamide Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LDLo | intraperitoneal | 1gm/kg (1000mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951. |
| cat | LDLo | oral | 150mg/kg (150mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 572, 1955. | |
| dog | LDLo | intraperitoneal | 1gm/kg (1000mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951. |
| guinea pig | LD50 | oral | 1730mg/kg (1730mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: TREMOR BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 47, Pg. 479, 1958. |
| guinea pig | LDLo | intraperitoneal | 1gm/kg (1000mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951. |
| mouse | LD50 | intraperitoneal | 180mg/kg (180mg/kg) | Bollettino Chimico Farmaceutico. Vol. 111, Pg. 293, 1972. | |
| mouse | LD50 | intravenous | 313mg/kg (313mg/kg) | BEHAVIORAL: GENERAL ANESTHETIC | Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951. |
| mouse | LD50 | oral | 300mg/kg (300mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 572, 1955. | |
| mouse | LD50 | subcutaneous | 300mg/kg (300mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 25, 1958. | |
| rabbit | LD50 | oral | 3200mg/kg (3200mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 572, 1955. | |
| rabbit | LDLo | intraperitoneal | 1gm/kg (1000mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951. |
| rat | LD50 | intraperitoneal | 600mg/kg (600mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 108, Pg. 450, 1953. | |
| rat | LD50 | oral | 980mg/kg (980mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 47, Pg. 479, 1958. |
Salicylamide Safety Profile
Hazard Codes: 
Xn
Risk Statements: 22-36/37/38-20/21/22
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36:Wear suitable protective clothing.
RIDADR: 3249
WGK Germany: 3
RTECS: VN6475000
HazardClass: 6.1(b)
PackingGroup of Salicylamide (CAS NO.65-45-2): III
Salicylamide Specification
Salicylamide (CAS NO.65-45-2), its Synonyms are 2-Hydroxybenzamide ; Benzamide, 2-hydroxy- ; 2-Carbamoylphenol ; 2-Carboxamidophenol ; Acket ; Afko-Sal ; Algamon ; Algiamida ; Allevin ; Amid kyseliny salicylove ; o-Hydroxybenzamide . It is odorless white or slightly pink crystals and bitter taste, leaves a sensation of warmth on the tongue.
What can I do for you?
Get Best Price
